Findings published in the American Journal of Pathology offer new directions for treatment of patients with Fuchs’ Endothelial Corneal Dystrophy (FECD)

Boston, Mass. —  Researchers from Massachusetts Eye and Ear have, for the first time, identified rapidly proliferating cells (known as “neural crest-derived progenitor cells”) in the corneal endothelium of specimens from normal corneas and from corneas with Fuchs’ Endothelial Corneal Dystrophy (FECD), a condition in which the cells responsible for keeping the cornea...

Researchers at Massachusetts Eye and Ear/Harvard Medical School have identified inflammatory factors that contribute to optic nerve damage following keratoprosthesis (KPro) implantation in a mouse model. They have also shown that blocking one of the factors, TNFa, leads to a significant decrease in optic nerve cell death, suggesting a new direction for preventing optic nerve damage in patients with keratoprosthesis implants.

BOSTON – Researchers from...

Findings could eventually lead to first non-surgical therapies and treatments for FECD. 

BOSTON -- Researchers at Schepens Eye Research Institute of Massachusetts Eye and Ear have shown a link between mitochondrial dysfunction in corneal endothelial cells and the development of Fuchs’ Endothelial Corneal Dystrophy (FECD)....

Peter Veldman, MD, of Mass. Eye and Ear was first author on two recent publications related to the S-stamp for Descemet membrane endothelial keratoplasty (DMEK), a novel orientation technique that has to date eliminated upside-down graft implantation in DMEK. Dr. Veldman helped to validate and then successfully implement this technique over the last...

Mass. Eye and Ear's Boston KPro was credited as the most widely used artificial cornea in an article from Ophthalmology Times on the use of bioengineered corneas.

September 1, 2015 Ophthalmology Times

Limbal stem cells -- identified with a new marker -- could reverse a leading cause of blindness

BOSTON (July 2, 2014) -- Boston researchers have identified a way to enhance regrowth of human corneal tissue to restore vision, using a molecule known as ABCB5 that acts as a marker for hard-to-find limbal stem cells. This work, a collaboration between the Massachusetts Eye and Ear/Schepens Eye Research Institute (Mass. Eye and Ear), Boston Children’s Hospital, Brigham and Women’s Hospital and the VA Boston Healthcare System, provides...